Pinder Sahota to step down as ABPI President

Pinder Sahota has made the decision to resign as President of the ABPI. He has made this decision to avoid an ongoing process around a Novo Nordisk ABPI Code of Practice breach becoming a distraction from the vital work of the ABPI.

Richard Torbett, Chief Executive, ABPI, said: “Pinder is a passionate advocate for the industry, and I want to thank him for his valuable contribution as ABPI President.

“I fully respect Pinder’s decision to step down as ABPI President which will in no way affect the ongoing case relating to Novo Nordisk. Any breach of the ABPI Code is taken extremely seriously and it is essential that all regulatory actions are robust, fair and transparent.”

ABPI Vice-President, Susan Rienow, Country President of Pfizer, will temporarily take on the roles and responsibilities of the ABPI President until a new President is chosen by the ABPI Board. 

Further information relating to the specifics of the PMCPA case relating to Novo Nordisk is available from the PMCPA website.

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.